Support
Fund the Research That Matters Most.
The Cedar Institute is donor-funded. Every dollar goes directly toward clinical science for neurodivergent populations.
Why Give
Why Your Support Matters
Psychedelic-assisted therapy is one of the most promising areas of mental health innovation in decades. Research is accelerating at King's College London, the University of Toronto, the University of Melbourne, Keio University in Tokyo, and in pharmaceutical pipelines targeting autism specifically. But the populations that may benefit most — autistic adults living with treatment-resistant depression, anxiety, and emotional dysregulation — still have almost no access to clinical trials, and the most pharmacologically relevant compound for their needs has been entirely overlooked. Your philanthropic support funds the studies that fill this gap. The researchers exist. The regulatory pathways exist. What is missing is funding.
Giving
How to Give
The Cedar Institute intends to apply for federal tax-exempt status under Section 501(c)(3). Contributions may not be tax-deductible until exempt status is granted. To discuss a gift, a multi-year pledge, or a grant from your foundation or donor-advised fund, contact us directly at [email protected]. We welcome conversations with family offices, private foundations, and individual donors who share our commitment to rigorous science and underserved populations.
Transparency
Where Your Money Goes
The Cedar Institute follows the Beckley Foundation model: we fund the delta, not the infrastructure. University partners provide laboratory space, regulatory permits, and personnel. We fund the incremental costs of the research itself.
Phase 0 — Instrument Validation
Psychometric validation of the Karame Four-Domain Assessment (K4DA). Operationalized scoring, reliability testing, convergent validity, normative data collection (n≥100 per group). Autistic advisory panel convened. Publication required before clinical deployment.
Estimated cost: €100K–€200K | Timeline: 12–18 months
Phase 1 — Pilot Characterization
Controlled pilot comparing acute effects of 2C-B (20mg) in autistic (n=25–30) vs. neurotypical (n=25–30) healthy volunteers using 7T fMRI, validated subjective experience measures, K4DA, and cardiovascular monitoring. Exploratory microdose arm (2mg). Leverages existing Maastricht infrastructure and Dutch regulatory approvals. DSMB oversight.
Estimated cost: €800K–€1.5M | Timeline: 18–24 months
Phase 2 — Protocol Pilot
Open-label pilot of the full Karame Protocol — three-tier dosing — in 16–20 autistic adults with documented trauma history and treatment-resistant depression/anxiety. Outcomes at baseline, post-treatment, 3-month, and 6-month follow-up. DSMB oversight.
Estimated cost: €500K–€1M | Timeline: 24–36 months
Total estimated funding through Phase 2 go/no-go decision: €1.4M–€2.7M
Phase 3 (controlled efficacy trial) will be funded based on Phase 2 results.
Research
Institutional Partners
We welcome research partnerships with universities and clinical research institutions that hold existing regulatory infrastructure for Schedule I psychedelic research. If your institution has an interest in neurodivergent populations and the capacity to conduct controlled human studies, we want to hear from you.
Ready to give?
The Cedar Institute does not currently accept online donations. All gifts are coordinated directly with our team to ensure donor intent is honored and properly acknowledged.
Tax deductibility
The Cedar Institute intends to apply for federal tax-exempt status under Section 501(c)(3). Contributions may not be tax-deductible until exempt status is granted.